140 related articles for article (PubMed ID: 22968441)
1. SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.
Dasgupta S; Jang JS; Shao C; Mukhopadhyay ND; Sokhi UK; Das SK; Brait M; Talbot C; Yung RC; Begum S; Westra WH; Hoque MO; Yang P; Yi JE; Lam S; Gazdar AF; Fisher PB; Jen J; Sidransky D
J Mol Med (Berl); 2013 Mar; 91(3):381-93. PubMed ID: 22968441
[TBL] [Abstract][Full Text] [Related]
2. Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.
Majumdar S; Gong EM; Di Vizio D; Dreyfuss J; Degraff DJ; Hager MH; Park PJ; Bellmunt J; Matusik RJ; Rosenberg JE; Adam RM
Neoplasia; 2013 Jul; 15(7):749-60. PubMed ID: 23814487
[TBL] [Abstract][Full Text] [Related]
3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
4. Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
Maiti GP; Mondal P; Mukherjee N; Ghosh A; Ghosh S; Dey S; Chakrabarty J; Roy A; Biswas J; Roychoudhury S; Panda CK
PLoS One; 2013; 8(5):e63440. PubMed ID: 23675485
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
[TBL] [Abstract][Full Text] [Related]
6. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
7. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
[TBL] [Abstract][Full Text] [Related]
8. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
9. Reduction of nuclear Y654-p-β-catenin expression through SH3GL2-meditated downregulation of EGFR in chemotolerance TNBC: Clinical and prognostic importance.
Islam MS; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Kumar Panda C
J Cell Physiol; 2020 Nov; 235(11):8114-8128. PubMed ID: 31960967
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective.
Gao X; Cai Y; Wang Z; He W; Cao S; Xu R; Chen H
J Transl Med; 2019 Sep; 17(1):308. PubMed ID: 31511014
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
12. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer.
Singh S; Trevino J; Bora-Singhal N; Coppola D; Haura E; Altiok S; Chellappan SP
Mol Cancer; 2012 Sep; 11():73. PubMed ID: 23009336
[TBL] [Abstract][Full Text] [Related]
13. SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.
Altenberger C; Heller G; Ziegler B; Tomasich E; Marhold M; Topakian T; Müllauer L; Heffeter P; Lang G; End-Pfützenreuter A; Döme B; Arns BM; Klepetko W; Zielinski CC; Zöchbauer-Müller S
Mol Cancer; 2017 Jan; 16(1):1. PubMed ID: 28093071
[TBL] [Abstract][Full Text] [Related]
14. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
Li M; Yang J; Zhang L; Tu S; Zhou X; Tan Z; Zhou W; He Y; Li Y
J Exp Clin Cancer Res; 2019 May; 38(1):211. PubMed ID: 31118055
[TBL] [Abstract][Full Text] [Related]
15. SOX7 is down-regulated in lung cancer.
Hayano T; Garg M; Yin D; Sudo M; Kawamata N; Shi S; Chien W; Ding LW; Leong G; Mori S; Xie D; Tan P; Koeffler HP
J Exp Clin Cancer Res; 2013 Apr; 32(1):17. PubMed ID: 23557216
[TBL] [Abstract][Full Text] [Related]
16. The regulation of Neuropilin 1 expression by miR-338-3p promotes non-small cell lung cancer via changes in EGFR signaling.
Ding Z; Zhu J; Zeng Y; Du W; Zhang Y; Tang H; Zheng Y; Qin H; Liu Z; Huang JA
Mol Carcinog; 2019 Jun; 58(6):1019-1032. PubMed ID: 30811684
[TBL] [Abstract][Full Text] [Related]
17. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
18. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
[TBL] [Abstract][Full Text] [Related]
19. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
20. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
